Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report
Open Access
- 28 February 2005
- journal article
- review article
- Published by BMJ in Journal of Medical Ethics
- Vol. 31 (3) , 144-148
- https://doi.org/10.1136/jme.2004.007229
Abstract
In September this year the Nuffield Council on Bioethics held a meeting to disclose and discuss the main findings of their newly published report on the ethical issues associated with developments in pharmacogenetics research. The basics of pharmacogenetics science is briefly outlined, and then the extent to which the report was successful in addressing (or at least highlighting) the attendant social, ethical, and policy implications of pharmacogenetics research is evaluated.Keywords
This publication has 32 references indexed in Scilit:
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarinThrombosis and Haemostasis, 2004
- The Drugs Don't WorkSocial Studies of Science, 2003
- Dyspepsia management in the millennium: to test and treat or not?Gut, 2003
- Genome-based pharmacogenetics and the pharmaceutical industryNature Reviews Drug Discovery, 2002
- Pharmacogenetics: Ethical Issues and Policy OptionsKennedy Institute of Ethics Journal, 2002
- Emerging Ethical Issues in PharmacogenomicsAmerican Journal of PharmacoGenomics, 2002
- Drug Target PharmacogenomicsAmerican Journal of PharmacoGenomics, 2001
- Ethical, Social and Legal Implications of Pharmacogenomics: A Critical ReviewPublic Health Genomics, 2001
- Informed Consent — Why Are Its Goals Imperfectly Realized?New England Journal of Medicine, 1980